These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 7954462

  • 41. Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine.
    Wagner S, Krepler C, Allwardt D, Latzka J, Strommer S, Scheiner O, Pehamberger H, Wiedermann U, Hafner C, Breiteneder H.
    Clin Cancer Res; 2008 Dec 15; 14(24):8178-83. PubMed ID: 19088033
    [Abstract] [Full Text] [Related]

  • 42. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
    Rinaldi M, Ria F, Parrella P, Signori E, Serra A, Ciafrè SA, Vespignani I, Lazzari M, Farace MG, Saglio G, Fazio VM.
    Cancer Res; 2001 Feb 15; 61(4):1555-62. PubMed ID: 11245465
    [Abstract] [Full Text] [Related]

  • 43. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
    Liu Y, Zheng M, Lai Z, Xiong D, Fan D, Xu Y, Peng H, Shao X, Xu Y, Yang M, Wang J, Liu H, Xie Y, Yang C, Zhu Z.
    Cancer Lett; 2004 Mar 18; 205(2):143-53. PubMed ID: 15036646
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities.
    Robinson RR, Chartier J, Chang CP, Horwitz AH, Better M.
    Hum Antibodies Hybridomas; 1991 Apr 18; 2(2):84-93. PubMed ID: 1873500
    [Abstract] [Full Text] [Related]

  • 47. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor activity in xenograft model of multiple myeloma.
    Tsunenari T, Akamatsu K, Kaiho S, Sato K, Tsuchiya M, Koishihara Y, Kishimoto T, Ohsugi Y.
    Anticancer Res; 1996 Apr 18; 16(5A):2537-44. PubMed ID: 8917348
    [Abstract] [Full Text] [Related]

  • 48. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens.
    Dhein J, Daniel PT, Trauth BC, Oehm A, Möller P, Krammer PH.
    J Immunol; 1992 Nov 15; 149(10):3166-73. PubMed ID: 1431095
    [Abstract] [Full Text] [Related]

  • 49. Preclinical studies on the pharmacokinetic properties of human monoclonal antibodies to colorectal cancer and their use for detection of tumors.
    McCabe RP, Peters LC, Haspel MV, Pomato N, Carrasquillo JA, Hanna MG.
    Cancer Res; 1988 Aug 01; 48(15):4348-53. PubMed ID: 3390831
    [Abstract] [Full Text] [Related]

  • 50. High-level expression and characterization of a mouse-human chimeric CD4 antibody with therapeutic potential.
    Looney JE, Knight DM, Arevalo-Moore M, Trinh H, Pak KY, Dalesandro MR, Rieber EP, Riethmuller G, Daddona PE, Ghrayeb J.
    Hum Antibodies Hybridomas; 1992 Oct 01; 3(4):191-200. PubMed ID: 1477300
    [Abstract] [Full Text] [Related]

  • 51. Monoclonal antibody to a human salivary gland adenocarcinoma cell line: augmentation of antibody-dependent cell-mediated cytotoxicity activity by streptococcal preparation OK-432 in human salivary gland adenocarcinoma-bearing nude mice given the antibody.
    Kaji R, Yoshida H, Yanagawa T, Sato M.
    J Biol Response Mod; 1989 Oct 01; 8(5):488-500. PubMed ID: 2552025
    [Abstract] [Full Text] [Related]

  • 52. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity.
    Liu AY, Robinson RR, Murray ED, Ledbetter JA, Hellström I, Hellström KE.
    J Immunol; 1987 Nov 15; 139(10):3521-6. PubMed ID: 3119711
    [Abstract] [Full Text] [Related]

  • 53. cDNA sequence analysis of monoclonal antibody FU-MK-1 specific for a transmembrane carcinoma-associated antigen, and construction of a mouse/human chimeric antibody.
    Arakawa F, Yamamoto T, Kanda H, Watanabe T, Kuroki M.
    Hybridoma; 1999 Apr 15; 18(2):131-8. PubMed ID: 10380012
    [Abstract] [Full Text] [Related]

  • 54. In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Le(a) (Le(a)/Le(a)) epitope.
    Watanabe M, Ohishi T, Kuzuoka M, Nudelman ED, Stroud MR, Kubota T, Kodairo S, Abe O, Hirohashi S, Shimosato Y.
    Cancer Res; 1991 Apr 15; 51(8):2199-204. PubMed ID: 1706961
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Penetration and binding of antibodies in experimental human solid tumors grown in mice.
    Ong GL, Mattes MJ.
    Cancer Res; 1989 Aug 01; 49(15):4264-73. PubMed ID: 2743313
    [Abstract] [Full Text] [Related]

  • 57. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma.
    Ellis JH, Barber KA, Tutt A, Hale C, Lewis AP, Glennie MJ, Stevenson GT, Crowe JS.
    J Immunol; 1995 Jul 15; 155(2):925-37. PubMed ID: 7608568
    [Abstract] [Full Text] [Related]

  • 58. Comparison of GK1.5 and chimeric rat/mouse GK1.5 anti-CD4 antibodies for prolongation of skin allograft survival and suppression of alloantibody production in mice.
    Rashid A, Auchincloss H, Sharon J.
    J Immunol; 1992 Mar 01; 148(5):1382-8. PubMed ID: 1538121
    [Abstract] [Full Text] [Related]

  • 59. In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.
    Pietersz GA, Wenjun L, Sutton VR, Burgess J, McKenzie IF, Zola H, Trapani JA.
    Cancer Immunol Immunother; 1995 Jul 01; 41(1):53-60. PubMed ID: 7543822
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.